StudyTeam follows trial subjects through to enrolment and offers visibility to sponsors at each step of the enrolment process.
OneStudyTeam has signed a collaboration with Antidote Technologies to offer an integrated, end-to-end patient referral management approach to sites and sponsors to provide control in patient recruitment in clinical trials.
OneStudyTeam will merge patient recruitment solutions with StudyTeam, its Cloud-based technology platform, and works directly with research sites, sponsors, and technology partners to reduce the burden on site staff.
An enrolment management solution, StudyTeam enables site personnel to log into a system to oversee enrolment across all patient sources and carry out trials effectively.
StudyTeam follows trial subjects through to enrolment and offers visibility to sponsors at each step of the enrolment process.
To identify the right patients for trials, Antidote merges technologies powered by data, digital capabilities, deep domain understanding, and a diversified partner network.
For optimising site workflows and offering referrals and patient demographic data directly into the StudyTeam platform, Antidote is merged with the Referral Partner Interface (RPI) of StudyTeam, which features a new race and ethnicity feature.
This enables sites to receive enhanced quality referrals in StudyTeam.
Sponsors can also obtain relevant enrolment information such as recruitment source traceability, patient source comparison, evaluate ROI on central advertising approaches, and understand the impact of recruitment on the diversity of patients.
OneStudyTeam CEO Ralph Passarella said: “Where OneStudyTeam provides visibility to measure and understand gaps in enrollment strategy, Antidote has mastered identifying those critical patients and matching them to the right trial.
“This collaboration spans the recruitment and enrollment continuum to drive diversity, equity, inclusion, and representation among trial candidates.”
In February 2019, Antidote Technologies and PatientPoint collaborated to enhance trial recruitment, leveraging point-of-care patient engagement tools.
